BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. The company is headquartered in Stony Brook, New York and currently employs 26 full-time employees. The company went IPO on 2001-08-24. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.
Quels sont les états financiers clés de BNB Plus Corp ?
Selon le dernier état financier (Form-10K), BNB Plus Corp a un total d'actifs de $0, un bénéfice net 損失 de $0
Quels sont les ratios financiers clés pour BNBX ?
Le ratio de liquidité de BNB Plus Corp est 0, la marge nette est 0, les ventes par action sont de $0.
Comment les revenus de BNB Plus Corp sont-ils répartis par segment ou géographie ?
BNB Plus Corp の最大収益セグメントは Deoxyribonucleic Acid Tagging and Security Products で、最新の利益発表における収益は 1,148,817 です。地域別に見ると、Asia and Other が BNB Plus Corp の主要市場であり、収益は 1,020,556 です。
BNB Plus Corp est-elle rentable ?
いいえ, selon les derniers états financiers, BNB Plus Corp a un bénéfice net 損失 de $0
BNB Plus Corp a-t-elle des passifs ?
いいえ, BNB Plus Corp a un passif de 0
Combien d'actions en circulation BNB Plus Corp a-t-elle ?
BNB Plus Corp a un total d'actions en circulation de 0